2 - TI Pharma

Haplotype 5
0 223 767 (724-813) 248 (235-263) 0.14 (0.13-0.15) 108 (101-115) 161 696 (637-760) 249 (232-267) 0.15 (0.13-0.17) 103 (94-114)
1 17 614 (515-760) 264 (226-308) 0.11 (0.09-0.14) 74 (62-88) 8 658 (553-783) 229 (191-274) 0.20 (0.14-0.29) 118 (91-154)
P 0.02 0.47 0.04 0.0001 0.53 0.38 0.13 0.33
Haplotype 6
0 231 764 (722-808) 248 (235-262) 0.14 (0.13-0.15) 106 (100-113) 155 690 (632-754) 249 (232-266) 0.15 (0.14-0.17) 104 (94-114)
1 9 518 (386-694) 294 (205-420) 0.10 (0.08-0.14) 68 (51-90) 14 751 (595-947) 240 (210-274) 0.14 (0.10-0.17) 106 (78-144)
P 0.011 0.36 0.04 0.003 0.49 0.62 0.49 0.87
For the haplotypes dummy variables indicating 0, 1 and 2 copies of each haplotype allele are shown. Data are estimated means (95% CI) unless otherwise
indicated. All variables were log transformed before analysis. P values were computed for additive models using linear generalized estimating equations,
which takes into account the family relatedness when computing the standard errors. First- and second-phase GSIS were adjusted for study center, family
relatedness, glucose tolerance status, age, BMI and ISI. ISI and DI were adjusted for study center, family relatedness, glucose tolerance status, age and BMI.
Significant findings are marked in bold. Abbreviations: GSIS: glucose-stimulated insulin secretion; ISI: insulin sensitivity index; DI: disposition index.
131
6
Chapter 6